{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T17:41:17.037808+00:00","company":{"ticker":"ZVRA","cik":1434647,"company_name":"ZEVRA THERAPEUTICS, INC."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"b3e99bb7fccac32485eee093b96af36d78e1cf4c","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.62 per basic and $0.60 diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$37.9 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$36.2 million"},"claim":"ZEVRA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $36.2 million, net income $37.9 million, EPS $0.62 per basic and $0.60 diluted share.","evidence_excerpt":"set forth by specific reference in any such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nZevra Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001434647-26-000029","anchor_url":"https://secwatch.observer/filing/0001434647-26-000029#claim-b3e99bb7fccac32485eee093b96af36d78e1cf4c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/0001434647-26-000029-index.htm"},{"fact_type":"material_agreement","fact_key":"6caaadf42b12d6e275f411d6f2eb7dbfc9888892","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2026-03-16T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Credit Agreement","agreement_type":"credit_facility","counterparty":"HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC","effective_date":"2026-03-12","item_codes_triggered":["1.02"],"value_text":"$63.0 million"},"claim":"ZEVRA THERAPEUTICS, INC. terminated Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC valued at $63.0 million (effective 2026-03-12).","evidence_excerpt":"On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001434647-26-000015","anchor_url":"https://secwatch.observer/filing/0001434647-26-000015#claim-6caaadf42b12d6e275f411d6f2eb7dbfc9888892","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm"},{"fact_type":"material_agreement","fact_key":"66c23b1119aad6665373932c05c6ffbb1c3fe35a","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2026-03-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase and Settlement Agreement","agreement_type":"asset_purchase","counterparty":"Commave Therapeutics SA","effective_date":"2026-03-13","item_codes_triggered":["1.01"],"value_text":"$50.0 million"},"claim":"ZEVRA THERAPEUTICS, INC. entered into Asset Purchase and Settlement Agreement with Commave Therapeutics SA valued at $50.0 million (effective 2026-03-13).","evidence_excerpt":"On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Collaboration and License Agreement between the parties dated September 3, 2019, as amended (the “AZSTARYS License Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001434647-26-000015","anchor_url":"https://secwatch.observer/filing/0001434647-26-000015#claim-66c23b1119aad6665373932c05c6ffbb1c3fe35a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/0001434647-26-000015-index.htm"},{"fact_type":"shareholder_vote","fact_key":"aaa5f185fe0f9cb6b081f0fa03dc331f18594538","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"failed","proposal_text":"Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan","proposal_type":"equity_plan","votes_abstain_text":"221,241","votes_against_text":"16,964,060","votes_for_text":"4,143,728"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders rejected Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan at the 2024-05-13 meeting.","evidence_excerpt":"4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-aaa5f185fe0f9cb6b081f0fa03dc331f18594538","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a8c3b60819fa0f0cc0345690da1789ff8d6e4d85","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Advisory approval of compensation of named executive officers","proposal_type":"say_on_pay","votes_abstain_text":"273,661","votes_against_text":"9,888,153","votes_for_text":"11,167,215"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-13 meeting.","evidence_excerpt":"3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-a8c3b60819fa0f0cc0345690da1789ff8d6e4d85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e956bde1306003b12c66b6fe9b6eaec090cd09e5","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024","proposal_type":"auditor_ratification","votes_abstain_text":"1,298,823","votes_against_text":"7,352,086","votes_for_text":"22,543,306"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-13 meeting.","evidence_excerpt":"2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company ’ s fiscal year ending December 31, 2024. 22,543,306 7,352,086 1,298,823 —","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-e956bde1306003b12c66b6fe9b6eaec090cd09e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"03367ac9e2a3ce227c223ac2713dddb8a4100208","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Election of Alvin Shih, M.D. as a Class III director","proposal_type":"director_election","votes_abstain_text":"9,865,186","votes_against_text":"4,736,877","votes_for_text":"16,592,152"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Alvin Shih, M.D. as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-03367ac9e2a3ce227c223ac2713dddb8a4100208","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0688704839e806eb896998afe648a5a5584a569a","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Election of Neil F. McFarlane as a Class III director","proposal_type":"director_election","votes_abstain_text":"9,865,186","votes_against_text":"8,915,201","votes_for_text":"12,413,828"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Neil F. McFarlane as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-0688704839e806eb896998afe648a5a5584a569a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"90eaecd0f1d33122eef4b4ce3827f95f4d0a0a61","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Election of Thomas D. Anderson as a Class III director","proposal_type":"director_election","votes_abstain_text":"9,865,186","votes_against_text":"6,062,268","votes_for_text":"15,266,761"},"claim":"ZEVRA THERAPEUTICS, INC. shareholders approved Election of Thomas D. Anderson as a Class III director at the 2024-05-13 meeting.","evidence_excerpt":"1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-016275","anchor_url":"https://secwatch.observer/filing/0001437749-24-016275#claim-90eaecd0f1d33122eef4b4ce3827f95f4d0a0a61","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm"},{"fact_type":"earnings_release","fact_key":"057cf09c7eadfa3f853010bc8b47b1e2214eb711","cik":1434647,"ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"($0.40) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($16.6) million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$3.4 million"},"claim":"ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: revenue $3.4 million, net income ($16.6) million, EPS ($0.40) per basic and diluted share.","evidence_excerpt":"patients currently enrolled and to preserve the value of the program while conducting our portfolio review. Overview of Q1 2024 Financial Results: Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. The components of revenue during the first quarter included $2.2 million in net reimbursements from the French EAP for","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-015210","anchor_url":"https://secwatch.observer/filing/0001437749-24-015210#claim-057cf09c7eadfa3f853010bc8b47b1e2214eb711","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm"}]}